Glycaemic Responses to Carbohydrate-rich Meals (GlyCarb)

Launched by QUADRAM INSTITUTE BIOSCIENCE · Mar 30, 2022

Keywords

ClinConnect Summary

The overarching aim of this project is to investigate a wide range of carbohydrate rich test meals (from 'off the shelf' commercially available products, through to enriched, restructured and re-formulated food products) on postprandial glycaemic response in normo-glycaemic individuals.

The 'remote' study protocol has been designed to maintain social distancing and thereby reduce risk of COVID19 transmission between participants and researchers during the ongoing outbreak. It also makes excellent use of continuous glucose monitoring devices, which enable continuous recording of participant...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women ≥ 18 years of age
• • Have access to/own a smartphone or tablet or computer and are willing to use this with apps needed for the study
• • BMI between 18 and 30 kg/m2 (calculated from self-reported height and weight)
• • Fasted HbA1C \< 42 mmol/mol (6.0%)
• • Willing to consume study foods (study foods and ingredients are discussed during the study talk)
• Exclusion Criteria:
• • Smokers of tobacco-based cigarettes or electronic cigarettes (or stopped smoking less than 6 months ago)
• • Gastro-intestinal disease/disorders e.g., Crohn's disease/ulcerative colitis
• • Other medical conditions that are judged to affect the study outcome or which may compromise the well-being of the participant e.g., active cancer, haemophilia. This will be assessed on a case-by-case basis.
• • Type 1 diabetes or insulin-dependent or non-insulin-dependent type 2 diabetes
• • Active infection with COVID-19, unless they are willing to postpone the screening until after the end of the self-isolation period (10 days from test or symptoms).
• • Prescribed and non-prescribed medications that may affect the study outcome or which may compromise the well-being of the participant e.g., warfarin, proton-pump inhibitors. This will be assessed on a case by-case-basis.
• • Dietary supplements that are judged to affect the study outcome unless the participant is willing to discontinue them for 4 weeks preceding the start of the study and for the duration of the study. This will be assessed on a case-by-case basis and includes protein supplements (shakes) or supplements that are not taken on a regular basis (on and off), particularly those containing ascorbic acid which may affect glucose readings.
• • Any known allergy, intolerance, or sensitivity to any food products oradhesives (for CGM application).
• • Those following a restrictive diet that may affect the study outcome (e.g., 5:2 diet) unless they are willing to suspend the diet for the duration of the study.
• • Women who are, or have been pregnant, within the last 12 months or who are breast-feeding
• • Parallel participation in another research project that involves dietary intervention.
• • Any person related to or living with any member of the study team.
• • Those who are part of the line manager/supervisory team of the Chief Investigator
• • Lack of capacity to provide written informed consent.
• • Clinical eligibility test results deemed by the CRF medical advisor to be indicative of a health problem which may compromise the well-being of the participant or which could affect the study outcome.